Home » Dr. Reddy’s, Rheoscience Announce Results From First Phase III Balaglitazone Trial
Dr. Reddy’s, Rheoscience Announce Results From First Phase III Balaglitazone Trial
Dr. Reddy’s Laboratories Ltd. and Rheoscience, a subsidiary of Nordic Bioscience A/S, Monday announced the headline results from the first phase
III study for their investigational agent, Balaglitazone.
RTTNews
RTTNews
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May